SHAREHOLDER ALERT: BSX NERV KNDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
January 17, 2021 at 10:12 AM EST
NEW YORK, NY / ACCESSWIRE / January 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Boston Scientific Corporation (NYSE:BSX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/boston-scientific-corporation-loss-submission-form-2?prid=12211&wire=1
Allegations against BSX include that: (i) the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional and threatened the continued viability of the entire product line; (ii) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Minerva Neurosciences, Inc. (NASDAQ:NERV)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?prid=12211&wire=1
Allegations against NERV include that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Kandi Technologies Group, Inc. (NASDAQ:KNDI)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/kandi-technologies-group-inc-loss-submission-form?prid=12211&wire=1
Allegations against KNDI include that: (i) Kandi artificially inflated its reported revenues through undisclosed related party transactions, or otherwise had relationships with key customers that indicated those customers did not have an arms length relationship with Kandi; (ii) the majority of Kandi's sales in the past year had been to undisclosed related parties and/or parties with such a close relationship and history with Kandi that it cast doubt on the arms-length nature of their relationship; (iii) all the foregoing, once revealed, was foreseeably likely to cast doubt on the validity of Kandi's reported revenues and, in turn, have a foreseeable negative impact on the Company's reputation and valuation; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: